Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 8/20 | 0.62 |
| ▸ | HCRTR1 | O43613 | 7/20 | 0.62 |
| ▸ | HTR7 | P34969 | 5/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL743443 | 0.88 | HCRTR2 (0.61) | HCRTR2HCRTR1HTR7MEN1KMT2A | |
| SCHEMBL745499 | 0.86 | HCRTR2 (0.62) | HCRTR2HCRTR1HTR7MEN1KMT2A | |
| SCHEMBL744594 | 0.86 | HCRTR2 (0.59) | HCRTR2HCRTR1HTR7MEN1KMT2A | |
| SCHEMBL746022 | 0.85 | HCRTR2 (0.60) | HCRTR2HCRTR1HTR7MEN1KMT2A | |
| SCHEMBL747465 | 0.84 | HCRTR2 (0.64) | HCRTR2HCRTR1HTR7MEN1KMT2A | |
| SCHEMBL743444 | 0.83 | HCRTR1 (0.64) | HCRTR2HCRTR1HTR7MEN1KMT2A | |
| SCHEMBL746921 | 0.83 | HCRTR2 (0.67) | HCRTR2HCRTR1HTR7MEN1KMT2A | |
| SCHEMBL744589 | 0.83 | HCRTR2 (0.67) | HCRTR2HCRTR1HTR7MEN1KMT2A | |
| SCHEMBL746800 | 0.83 | HCRTR2 (0.60) | HCRTR2HCRTR1HTR7MEN1KMT2A | |
| SCHEMBL747161 | 0.81 | HCRTR1 (0.59) | HCRTR2HCRTR1MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7223754-B2 | Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders | DYNOGEN PHARMACEUTICALS, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-20070066597-A1 | Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders | DYNOGEN PHARMACEUTICALS, INC. (US) | 2007-03-22 | — | — | US | disclosed |
| US-20050148587-A1 | Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders | DYNOGEN PHARMACEUTICALS, INC. (US) | 2005-07-07 | — | — | US | disclosed |
| US-20050113421-A1 | Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating non-inflammatory gastrointestinal tract disorders | DYNOGEN PHARMACEUTICALS, INC. (US) | 2005-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113421-A1 | Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating non-inflammatory gastrointestinal tract disorders | TRPV2, RYR2, VDAC2 | HCRTR2 194/4885HCRTR1 1608/4885HTR7 1424/4885 |
| US-20070066597-A1 | Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders | RYR2, CACNB2, CACNA1I | HCRTR2 251/4885HCRTR1 2195/4885HTR7 2363/4885 |
| US-20050148587-A1 | Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders | RYR2, CACNB2, CACNA1I | HCRTR2 251/4885HCRTR1 2195/4885HTR7 2363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.